Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it. The smooth operation of the drug distribution chain in Algeria is compromised by its multiplicity of actors – from…
MENA The Middle East and North Africa (MENA) region’s pharmaceutical market is projected to reach a value of around USD 60 billion by 2025 according to reporting from TradeArabia. The most impressive growth is coming from the UAE, but North African giants Egypt and Algeria are also significant contributors. Factors…
Korea LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines, biosimilars, biologics, and dermo-cosmetics. Its president, Dr Son, explains the reason why he joined the company, his strategy to turn it into a truly global entity, and its…
Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken to ensure all Algerian cancer patients can receive the care they need. It is undeniable that tangible progress has…
Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…
Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker
Algeria Adlane Soudani, general manager of Ipsen’s Algerian affiliate, lifts the lid on Ipsen’s ambitions for the local market, and the company’s parallel strategies to ramp up local production while simultaneously delivering tech transfer to local partners. Our rather distinctive approach is to deploy parallel strategies: we will maintain our…
Algeria Ipsen’s Guillaume Freneuil gives his take on the importance of the Algerian market to the global group. If we are investing right now in Algeria it is because we envisage further growth here to be able to serve patient needs 33 percent of Sales within Ipsen are now in…
Algeria Click here to download the Healthcare & Life Sciences Review Algeria 2019 report. Algeria, Africa’s largest country by area, stands as a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out…
Algeria Mehdi Ferdjioui, GM for North West Africa at GE Healthcare explains the importance of his region to the global group and how GE’s innovative medtech solutions plug into helping solve some of Algeria’s most pressing healthcare needs. Part of our success is due to the GE group’s deep-rooted ties…
Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria. From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…
Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…
See our Cookie Privacy Policy Here
